References
- Regulation (EU. 2017/745 Of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. OJ L. 2017;117:1–175.
- Regulation (EU. No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. OJ L. 2014;158:1–76.
- Code of Federal Regulations (CFR). Title 21, Part 312 - Investigational New Drug Application. U.S. Food and Drug Administration. [cited 2023 May 7]. Available at https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=4e36990a5a57b3d4b4f96bfe6170b59e&ty=HTML&h=L&mc=true&=PART&n=pt21.5.312.
- Code of Federal Regulations (CFR). Title 21, Part 812 - Investigational Device Exemptions. U.S. Food and Drug Administration. [cited 2023 May 7]. Available at https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=1&SID=4e36990a5a57b3d4b4f96bfe6170b59e&ty=HTML&h=L&mc=true&=PART&n=pt21.8.812.
- Ray WA, Stein CM. Reform of drug regulation–beyond an independent drug-safety board. N Engl J Med. 2006;354(2):194–201. doi: 10.1056/NEJMsb053432.
- Okie S. Safety in numbers—monitoring risk in approved drugs. N Engl J Med. 2005;352(12):1173–1176. doi: 10.1056/NEJMp058029.
- Vasko P, Alfredsson J, Bäck M, et al. SWEDEHEART Annual Report 2022. [cited 2023 May 6]. Available at https://www.ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh.
- The Swedish Coronary Angiography and Angioplasty Registry (SCAAR). [cited 2023 May 6]. Available at https://www.ucr.uu.se/swedeheart/start-scaar.
- The Swedish Heart Failure Registry (SwedeHF). [cited 2023 May 6]. Available at http://www.ucr.uu.se/rikssvikt-en/.
- Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010;19(6):537–554. doi: 10.1002/pds.1908.
- Omerovic E, Erlinge D, Koul S, et al. Rationale and design of switch swedeheart: a registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome. Am Heart J. 2022;251:70–77. doi: 10.1016/j.ahj.2022.05.017.